Incannex Healthcare: On January 17, 2024, Incannex Healthcare Inc. Announced That It Received Approval From An Institutional Review Board With Respect To Its Protocol To Commence A Phase 2/3 Clinical Trial To Assess The Safety And Efficacy Of Proprietary Combination Drug Candidate Ihl42x In Patients With Obstructive Sleep Apnea. Further Information Is Included In The Press Release Attached As Exhibit 99.1 Hereto, Which Is Incorporated By Reference Into This Item 8.01, Financial Statements And Exhibits
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameIncannex Healthcare Limited (formerly Impression Healthcare Limited)
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









